SEC Comment Letter for TuHURA Biosciences, (HURA) — Apr 8, 2013
TuHURA Biosciences, Inc./NV (HURA) (CIK 0001498382)
Date: April 8, 2013 · CIK: 0001498382 · Accession: 0000000000-13-018683
AI Filing Summary & Sentiment
Reasoning
Letter
April 8, 2013 Via E -Mail Jeffrey Bacha Chief Executive Officer and President DelMar Pharmaceuticals, Inc. Suite 720 -999 West Broadway Vancouver, BC Canada V5Z 1K5
Re: DelMar Pharmaceuticals, Inc. Current Report on Form 8-K Filed January 31 , 2013 , as amended File No. 000 -54801
Dear Mr. Bacha :
We have completed our review of your filing . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.
Sincerely,
/s/ Jennifer Riegel for
Show Raw Text
April 8, 2013 Via E -Mail Jeffrey Bacha Chief Executive Officer and President DelMar Pharmaceuticals, Inc. Suite 720 -999 West Broadway Vancouver, BC Canada V5Z 1K5 Re: DelMar Pharmaceuticals, Inc. Current Report on Form 8-K Filed January 31 , 2013 , as amended File No. 000 -54801 Dear Mr. Bacha : We have completed our review of your filing . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely, /s/ Jennifer Riegel for Jeffrey P. Riedler Assistant Director cc: Via E -Mail Jeff Cahlon Sichenzia Ross Friedman Ference LLP 61 Broadway New York, NY 10006